Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures~2. Female or male aged 18 to 65 years, inclusively, at the time of enrolment.~3. General good health~4. Mild, stable, allergic asthma and asthma therapy limited to inhaled, short-acting beta 2 agonists (not more than twice weekly)~5. Positive skin-prick test to at least one common aeroallergen~Exclusion Criteria:~1. Current lung disease other than mild allergic asthma~2. Any history or symptoms of disease, including, but not limited to, cardiovascular, neurologic, autoimmune or haematologic~3. Any clinically significant abnormal findings in laboratory test results in complete blood count, coagulation, chemistry panel and urinalysis at enrolment and during screening period~4. History of anaphylaxis to any biologic therapy or vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Benralizumab (Type: EXPERIMENTAL): Benralizumab administered subcutaneously
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).